Growth-hormone-axis research
Ipamorelin
Early human researchIpamorelin is a short peptide that interacts with the ghrelin receptor. It has been studied for growth-hormone release and gastrointestinal effects. Receptor selectivity does not mean absence of risk.
Source review: September 9, 2026. Scientific evidence and trial records change over time.
01 · What is it?
The identity comes first.
Ipamorelin is a short peptide that interacts with the ghrelin receptor. It has been studied for growth-hormone release and gastrointestinal effects. Receptor selectivity does not mean absence of risk.
Scientific classification: Synthetic pentapeptide; growth-hormone secretagogue
For example. It rings a different doorbell at the hormone-release department from a GHRH analogue.
02 · How does it work?
The signal, explained.
It activates the ghrelin receptor, which can prompt growth-hormone release and also participates in digestive signaling. These effects depend on the tissue and hormonal setting.
The key research focus is Ghrelin receptor (GHSR-1a). A target describes where an interaction may occur; it does not by itself establish a benefit.
Learn the Science · mechanism
GHSR-1a agonism can activate Gq/PLC/IP3/calcium signaling and stimulate pituitary growth-hormone release. Effects depend on tissue and endocrine context.
03 · What happens after the signal?
Follow the downstream effects.
Increased GH can influence hepatic IGF-1 and broader endocrine feedback. Ghrelin-receptor pathways also intersect with gastrointestinal and appetite physiology.
To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.
04 · What is it commonly researched for?
The questions researchers are asking.
Researchers have investigated endocrine responses and gastrointestinal motility in clinical development.
These are areas of investigation, not promises about a Maison product.
05 · Body systems involved
Where the biology connects.
- Pituitary
- Releases hormones in response to hypothalamic and receptor signals.
- Digestive tract
- Relevant to secretion, motility, epithelial transport or gut–brain signaling.
- Liver
- A central site of nutrient handling, metabolic enzymes and selected downstream hormone responses.
06 · Receptor / target profile
The molecular reference card.
- Primary receptor or target
- Ghrelin receptor (GHSR-1a)
- Secondary interactions
- No additional primary target established for the research claim discussed.
- Where it is found
- Pituitary and hypothalamic circuits, with gastrointestinal-related signaling.
- Activation, inhibition or interaction
- GHSR-1a agonism can activate Gq/PLC/IP3/calcium signaling and stimulate pituitary growth-hormone release. Effects depend on tissue and endocrine context.
- Important downstream pathways
- Increased GH can influence hepatic IGF-1 and broader endocrine feedback. Ghrelin-receptor pathways also intersect with gastrointestinal and appetite physiology.
07 · Evidence quality
What carries weight—and what does not.
STRONGER EVIDENCE
Convincing replicated human evidence for the broad wellness claims is not established.
EMERGING HUMAN EVIDENCE
A randomized postoperative-ileus study did not show statistically significant efficacy on its primary endpoint. This clinical exposure does not establish bodybuilding benefit or long-term safety.
EARLY / PRECLINICAL EVIDENCE
The mechanistic observations described above do not establish the same outcomes in people.
UNKNOWN OR NOT WELL ESTABLISHED
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.
08 · Who is studying it?
Follow the original research.
No current sponsor-led clinical development program was verified for this exact research identity. This does not prove that no study exists; consult current records and distinguish related molecules.
Regulatory context: No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
VIEW CURRENT CLINICAL TRIALSRegistry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.
09 · Research terminology
A small glossary for this page.
Target
The molecule or biological structure a compound interacts with.
Pathway
A sequence of cellular events connecting a signal to a response.
Preclinical
Research outside human clinical trials, including cells and animals.
Gq
A G protein that can activate phospholipase C and calcium-related signaling.
PLC
Phospholipase C: an enzyme that generates intracellular signaling molecules from membrane lipids.
IP3
A small messenger that can release calcium from storage inside a cell.
IGF-1
Insulin-like growth factor 1: a hormone influenced by growth hormone, with growth and metabolic signaling roles.
endocrine
Relating to hormone signaling between tissues.
Biomarker
A measurable biological feature. A change in a marker does not always translate into a meaningful health outcome.
Target engagement
Evidence that a compound actually reaches and interacts with the intended biological target.
Randomized controlled trial
A study that assigns participants by chance to comparison groups, helping separate an intervention’s effects from other influences.
10 · Research status & limitations
Keep the boundaries visible.
No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
The main evidence category here is early human research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.
11 · References / continue reading
Go to the source.
Individual study links support the associated research discussion. Literature-search links are clearly labelled and help you explore further; they are not themselves proof of a claim. Sponsor announcements should be read alongside published papers and current regulatory records.